Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:3
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 2 od 10  
Back povratak na rezultate
2020, vol. 37, br. 2, str. 121-130
Klinički relevantni obrasci kardiovaskularnih komorbiditeta kod bolesnika sa HOBP - da li su uopšte važni?
aKlinički centar Niš, Klinika za plućne bolesti + Univerzitet u Nišu, Medicinski fakultet
bKlinički centar Niš, Klinika za plućne bolesti + Klinički centar Niš, Klinika za opštu hirurgiju
cKlinički centar Niš, Klinika za kardiovaskularne bolesti + Univerzitet u Nišu, Medicinski fakultet

e-adresaborislavbozanic@gmail.com
Ključne reči: hronična opstruktivna bolest pluća; kardiovaskularni komorbiditeti; hronična inflamacija
Sažetak
Udruženost hronične opstruktivne bolesti pluća (HOBP) i kardiovaskularnih bolesti uočena je tokom proučavanja sistemskih posledica ove bolesti. Među obolelima, značajno je veća incidencija, a veći je i mortalitet od kardiovaskularnih bolesti, dok redukcija kardiovaskularnog rizika predstavlja važno polje za smanjenje sveukupnog mortaliteta od HOBP. Kompleksni patofiziološki mehanizmi interakcije respiratornog sistema i kardiovaskularnog sistema, tokom akutizacije HOBP još uvek nisu dovoljno proučeni, a njihova klinička ispoljavanja predstavljaju sve veći izazov u savremenoj dijagnostici i terapiji. Studije pokazuju to da intenziviranje sistemskog inflamatornog odgovora u akutnoj egzacerbaciji HOBP rezultira endotelnom disfunkcijom, aktivacijom aterosklerotskih plakova, većom podložnošću ka formiranju tromba i rupturi, što je posredan, ali veoma značajan uzrok akutnih kardiovaskularnih događaja. Akutna pogoršanja HOBP mogu biti okidači za akutni kardiovaskularni događaj, ali mogu i sama biti pokrenuta prethodnim kardiovaskularnim dešavanjem. Uprkos unapređenim dijagnostičko-terapijskim postupcima, ova dvosmerna povezanost često ostaje neprepoznata. Efekat tretmana HOBP na koegzistirajuću vulnerabilnost kardiovaskularnog sistema još uvek nije u potpunosti razjašnjen. I pored sigurnih dokaza, koji potkrepljuju vezu između HOBP i kardiovaskularnih bolesti, savremene terapijske opcije ciljanog lečenja ovih bolesti još uvek su u fazi istraživanja, bez relevantnijih randomizovanih kliničkih ispitivanja na ovu temu. Prvi rezultati Summit studije obećavaju adekvatniji tretman ovih bolesnika.
Reference
Anthonisen, N.R., Connett, J.E., Enright, P.L., Manfreda, J. (2002) Hospitalizations and mortality in the lung health study. American Journal of Respiratory and Critical Care Medicine, 166(3): 333-339
Appleton, S., Jones, T., Poole, P., Pilotto, L., Adams, R., Lasserson, T.J., Smith, B.J., Muhammed, J. (2006) Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, (3): CD001387
Bertoletti, L., Quenet, S., Mismetti, P., Hernández, L., Martín-Villasclaras, J.J., Tolosa, C., Valdés, M., Barrón, M., Todolí, J.A., Monreal, M. (2012) Clinical presentation and outcome of venous thromboembolism in COPD. European Respiratory Journal, 39(4): 862-868
Boschetto, P., Beghé, B., Fabbri, L.M., Ceconi, C. (2012) Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice. Respirology, 17(3): 422-431
Brekke, P.H., Omland, T., Smith, P., Søyseth, V. (2008) Underdiagnosis of myocardial infarction in COPD: Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respiratory Medicine, 102(9): 1243-1247
Bursi, F., Vassallo, R., Weston, S.A., Killian, J.M., Roger, V.L. (2010) Chronic obstructive pulmonary disease after myocardial infarction in the community. American Heart Journal, 160(1): 95-101
Calverley, P.M.A., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., Crim, C., Willits, L.R., Yates, J.C., Vestbo, J. (2010) Cardiovascular events in patients with COPD: TORCH Study results. Thorax, 65(8): 719-725
Camiciottoli, G., Bigazzi, F., Magni, C., Bonti, V., Diciotti, S., Bartolucci, M., Mascalchi, M., Pistolesi, M. (2016) Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease, Volume 11: 2229-2236
Cao, C., Wang, R., Wang, J., Bunjhoo, H., Xu, Y., Xiong, W. (2012) Body mass index and mortality in chronic obstructive pulmonary disease: A meta-analysis. PLoS One, 7: 1-8
Ciric, Z., Stankovic, I., Pejcic, T., et al. (2013) Nutrition disorders and systemic inflammation in patients with chronic obstructive pulmonary disease. Med Glas, 10(2): 266-71, PMID: 23892843
Cui, H., Miao, D.M., Wei, M.Z., et al. (2012) Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010. J Geriatr Cardiol, 9(1): 5-10
de Lucas-Ramos, P., Izquierdo-Alonso, J.L., Rodriguez-Gonzalez, M.J.M., et al. (2008) Cardiovascular risk factors in chronic obstructive pulmonary disease: Results of the ARCE study. Arch Bronconeumol, 44: 233-241
Decramer, M.L., Hanania, N.A., Lötvall, J.O., Yawn, B. (2013) The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease, 8: 53-64
Díez-Manglano, J., Barquero-Romero, J., Almagro, P., Cabrera, F.J., López, G.F., Montero, L., Soriano, J.B. (2014) COPD patients with and without metabolic syndrome: Clinical and functional differences. Internal and Emergency Medicine, 9(4): 419-425
Divo, M., Cote, C., de Torres, J.P., Casanova, C., Marin, J.M., Pinto-Plata, V., Zulueta, J., Cabrera, C., Zagaceta, J., Hunninghake, G., Celli, B. (2012) Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 186(2): 155-161
Donaldson, G.C., Hurst, J.R., Smith, C.J., Hubbard, R.B., Wedzicha, J.A. (2010) Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest, 137(5): 1091-1097
Etminan, M., Jafari, S., Carleton, B., Fitzgerald, J.M. (2012) Beta-blocker use and COPD mortality: A systematic review and meta-analysis. BMC Pulmonary Medicine, 12(1): 48-48
Finkelstein, J., Cha, E., Scharf, S.M. (2009) Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. International Journal of Chronic Obstructive Pulmonary Disease, 4: 337-49
Ford, E.S., Wheaton, A.G., Mannino, D.M., Presley-Cantrell, L., Li, C., Croft, J.B. (2012) Elevated cardiovascular risk among adults with obstructive and restrictive airway functioning in the United States: A cross-sectional study of the National Health and Nutrition Examination Survey from 2007-2010. Respiratory Research, 13(1): 115-115
García-Olmos, L., Alberquilla, Á., Ayala, V., García-Sagredo, P., Morales, L., Carmona, M., de Tena-Dávila, M.J., Pascual, M., Muñoz, A., Salvador, C.H., Monteagudo, J.L. (2013) Comorbidity in patients with chronic obstructive pulmonary disease in family practice: A cross sectional study. BMC Family Practice, 14(1): 11-11
Held, C., Iqbal, C., Lear, S.A., et al. (2012) Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: Results of the INTERHEART study. Eur Heart J, 33(4): 452-66
Hogg, J.C., Timens, W. (2009) The pathology of chronic obstructive pulmonary disease. Annual Review of Pathology: Mechanisms of Disease, 4(1): 435-459
Huiart, L., Ernst, P., Ranoui, X., et al. (2005) Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. European Respiratory Journal, 25(4): 634-639
Kido, T., Tamagawa, E., Bai, N., Suda, K., Yang, H.C., Li, Y., Chiang, G., Yatera, K., Mukae, H., Sin, D.D., van Eeden, S.F. (2011) Particulate matter induces translocation of IL-6 from the lung to the systemic circulation. American Journal of Respiratory Cell and Molecular Biology, 44(2): 197-204
Lahousse, L., Loth, D.W., Joos, G.F., Hofman, A., Leufkens, H.G.M., Brusselle, G.G., Stricker, B.H. (2013) Statins, systemic inflammation and risk of death in COPD: The Rotterdam study. Pulmonary Pharmacology & Therapeutics, 26(2): 212-217
Mancini, G.B. J., Etminan, M., Zhang, B., Levesque, L.E., Fitzgerald, J. M., Brophy, J.M. (2006) Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. Journal of the American College of Cardiology, 47(12): 2554-2560
Marchetti, N., Ciccolella, D.E., Jacobs, M.R., Crookshank, A., Gaughan, J.P., Kashem, M.A., Bove, A.A., Criner, G.J. (2011) Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD: Journal of Chronic Obstructive Pulmonary Disease, 8(2): 60-65
McMurray, J.J.V., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., Gomez-Sanchez, M.A., Jaarsma, T., Kober, L., Lip, G.Y.H., Maggioni, A.P., Parkhomenko, A., Pieske, B.M., Popescu, B.A., Ronnevik, P.K. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: Developed in collaboration with the. European Heart Journal, 33(14): 1787-1847
Morgan, A.D., Zakeri, R., Quint, J.K. (2018) Defining the relationship between COPD and CVD: What are the implications for clinical practice?. Therapeutic Advances in Respiratory Disease, 12: 1-16
Mortensen, E.M., Copeland, L.A., Pugh, M.J.V., Restrepo, M.I., de Molina, R.M., Nakashima, B., Anzueto, A. (2009) Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respiratory Research, 10(1): 45-45
Mullerova, H., Agusti, A., Erqou, S., et al. (2013) Cardiovascular comorbidity in chronic obstructive pulmonary disease: Systematic literature review. Chest, 144: 1163-78
O'Donnell, C.J., Elosua, R. (2008) Cardiovascular risk factors: Insights from Framingham heart study. Revista Española de Cardiología (English Edition), 61(3): 299-310
Poulain, M., Doucet, M., Major, G.C., Drapeau, V., Sériès, F., Boulet, L., Tremblay, A., Maltais, F. (2006) The effect of obesity on chronic respiratory diseases: Pathophysiology and therapeutic strategies. Canadian Medical Association Journal, 174(9): 1293-1299
Quint, J. (2017) The Relationship between COPD and cardiovascular disease. Tanaffos, 16(Suppl 1): S16-S17, PMID: 29158754
Radovic, M., Ristic, L., Ciric, Z., Dinic, R.V., Stankovic, I., Pejcic, T., Rancic, M., Bogdanovic, D. (2016) Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis: Limitations for the underlying COPD detection. International Journal of Chronic Obstructive Pulmonary Disease, 11(1): 1307-16
Reed, R.M., Eberlein, M., Girgis, R.E., Hashmi, S., Iacono, A., Jones, S., Netzer, G., Scharf, S. (2012) Coronary artery disease is under-diagnosed and under-treated in advanced lung disease. American Journal of Medicine, 125(12): 1228.e13-1228.e22
Roca, M., Verduri, A., Corbetta, L., Clini, E., Fabbri, L.M., Beghé, B. (2013) Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. European Journal of Clinical Investigation, 43(5): 510-521
Roversi, S., Roversi, P., Spadafora, G., Rossi, R., Fabbri, L.M. (2014) Coronary artery disease concomitant with chronic obstructive pulmonary disease. European Journal of Clinical Investigation, 44(1): 93-102
Schnell, K., Weiss, C.O., Lee, T., Krishnan, J.A., Leff, B., Wolff, J.L., Boyd, C. (2012) The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: A cross-sectional study using data from NHANES 1999-2008. BMC Pulmonary Medicine, 12(1): 26-26
Sevenoaks, M.J., Stockley, R.A. (2006) Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity: A common inflammatory phenotype?. Respiratory Research, 7(1): 70
Singh, D., Agusti, A., Anzueto, A., Barnes, P.J., Bourbeau, J., Celli, B.R., Criner, G.J., Frith, P., Halpin, D.M.G., Han, M., López, V.M. V., Martinez, F., Montes, de O.M., Papi, A., Pavord, I.D. (2019) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: The GOLD science committee report 2019. European Respiratory Journal, 53(5): pii: 1900164
Stanković, I., Ćirić, Z., Radović, M. (2011) Asthma exacerbations and viruses. Acta facultatis medicae Naissensis, vol. 28, br. 4, str. 241-244
van Eeden, S.F., Sin, D.D. (2008) Chronic obstructive pulmonary disease: A chronic systemic inflammatory disease. Respiration, 75(2): 224-238
Vestbo, J., Anderson, J., Brook, R.D., Calverley, P.M.A., Celli, B.R., Crim, C., Haumann, B., Martinez, F.J., Yates, J., Newby, D.E. (2013) The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. European Respiratory Journal, 41(5): 1017-1022
Yuji, H., Toshiyuki, Y., Noritsugu, H., Ryuji, S., Hiroyuki, S., Takashi, I., Takayuki, M., Masato, M., Katsuyuki, T., Yuji, T., Kanji, F. (2011) Clinical and inflammatory factors associated with body mass index in elderly patients with chronic obstructive pulmonary disease. Geriatrics & Gerontology International, 11(1): 32-38
 

O članku

jezik rada: engleski
vrsta rada: pregledni članak
DOI: 10.5937/afmnai37-24184
objavljen u SCIndeksu: 06.08.2020.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0